Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a pivotal Phase 3 clinical study ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled ‘Phase 3, ...

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).

OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy ...

A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

Professor Guan Xinyuan (left) and his research team developed the 'Cancer Immunology Data Engine', which is publicly ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Cambridge, Massachusetts Friday, October 24, 2025, 18:00 Hrs [IST] ...

Detailed price information for Coya Therapeutics Inc (COYA-Q) from The Globe and Mail including charting and trades.

Globe Investor value reports provide a daily price target for more than 9,000 stocks on the TSX, Nasdaq, and NYSE. Used by Bay Street pros, advisors and Canadians who invest on their own, they help ...

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...